RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Condition:   Thyroid Cancer
Interventions:   Drug: Durvalumab (Medi4736);   Radiation: Radioiodine (RAI)
Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca;   MedImmune LLC
Recruiting - verified July 2017

http://ift.tt/2uR0e18